Use this url to cite publication: https://hdl.handle.net/20.500.12512/18079
Options
Comparison of muscle-derived stem/progenitor cells and bone marrow mesenchymal stem cells for the treatment of acute kidney injury / Egle Pavyde, Romaldas Maciulaitis, Ernesta Ivanauskaite Didziokiene, Neringa Sutkeviciene, Justinas Maciulaitis, Mantas Malinauskas, Judita Zymantiene, Maksim Bratchikov, Arvydas Usas
Type of publication
Konferencijų tezės nerecenzuojamame leidinyje / Conference theses in non-peer-reviewed publication (T2)
Author(s)
Ivanauskaitė Didžiokienė, Ernesta | Viešoji įstaiga Vilniaus universiteto ligoninės Santariškių klinikos |
Bratčikov, Maksim | Valstybinis mokslinių tyrimų institutas Inovatyvios medicinos centras |
Title
Comparison of muscle-derived stem/progenitor cells and bone marrow mesenchymal stem cells for the treatment of acute kidney injury / Egle Pavyde, Romaldas Maciulaitis, Ernesta Ivanauskaite Didziokiene, Neringa Sutkeviciene, Justinas Maciulaitis, Mantas Malinauskas, Judita Zymantiene, Maksim Bratchikov, Arvydas Usas
Publisher (trusted)
Lithuanian university of Health Sciences |
Date Issued
Date Issued |
---|
2016-10-20 |
Extent
p. 19-19.
Is part of
The 7th International Pharmaceutical Conference Science and practice 2016, dedicated to the 240th anniversary of prof. Johann Friedrich Wolfgang : book of abstracts : October 20-21, 2016, Kaunas, Lithuania / Faculty of Pharmacy of Lithuanian university of Health Sciences [et al.]. Kaunas : Lithuanian university of Health Sciences, 2016. ISBN 9789955154549.
Version
Originalus / Original
Description
ISBN 978-9955-15-454-9.
Bibliogr.: p. 19
Field of Science
Abstract
Introduction. The skeletal muscle-derived stem/progenitor cells (MDSPCs) have been thoroughly investigated in preclinical studies. However, the therapeutic potential of MDSPCs for acute kidney injury (AKI) has only been evaluated by our research group. We aimed to compare MDSPCs with bone marrow mesenchymal stem cells (BM-MSCs) and to evaluate their feasibility for the treatment of AKI. Materials and methods. Rats were randomly assigned to one of four groups: healthy controls, AKI group, AKI treated with MDSPCs, AKI treated with BM-MSCs. AKI was induced by gentamicin (80 mg/kg/day; i.p.) for 7 consecutive days. PKH-26-labeled MDSPCs and BM-MSCs (1X106 cells/animal) were injected intravenously 24 hours after the last gentamicin injection. Physiological and histological kidney parameters were determined on day 0, 8, 14m 21m 28, 35 (6 animals per time point). Results. Both, MDSPCs and BM-MSCs accelerated functional kidney recovery and regeneration, as reflected by significantly lower serum creatinine levels and renal injury scoring, higher urinary creatinine and GFR levels (p<0.05) compared with the nontreated AKI group. PKH-26 labelled MDSPCs and BM-MSCs were present in the renal cortex on day 9, day 21 and day 35, indicating the capacity of both cell types to migrate and populate the renal tissue. There was no significant difference in any parameters between MDSPCs and BM-MSCs at any time points (p>0.05). [...].
Type of document
type::text::conference output::conference proceedings::conference paper
ISBN (of the container)
9789955154549
Other Identifier(s)
(LSMU ALMA)990000913560107106
Coverage Spatial
Lietuva / Lithuania (LT)
Language
Anglų / English (en)
Bibliographic Details
3